← ANALYST RATINGS · TIPRANKS
ANI Pharmaceuticals (ANIP): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy2 Hold0 Sell
Ratings of 8 analysts in the last 3 months12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $107, the highest $121, the lowest $85.00. The average is +47.7% from the last price of $72.29.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Vamil Divan★★★★★★★★★★#458 · hits 59% · avg +13.5% | Guggenheim | $119 | Buy | +64.6% | Reiterated | 05.10.26on TipRanks Oct 6 10:10 | −0.1%next day −2.0% · 5 days +1.0% | ↗ |
| Les Sulewski★★★★★★★★★★#1947 · hits 51% · avg +11.5% | Truist Financial | $85.00 | Hold | +17.6% | Initiated | 23.09.26on TipRanks Sep 28 21:02 | −3.7%next day −0.4% · 5 days −1.7% | ↗ |
| Brandon Folkes★★★★★★★★★★#10500 · hits 39% · avg −1.1% | H.C. Wainwright | $121 | Buy | +67.4% | Reiterated | 21.09.26on TipRanks 13:55 | +2.0%next day −1.2% · 5 days −4.1% | ↗ |
| Daniel Clark★★★★★★★★★★#3492 · hits 65% · avg +17.4% | Leerink Partners | $104 | Buy | +43.9% | Initiated | 09.09.26on TipRanks 08:20 | +1.1%next day +1.7% · 5 days +5.2% | ↗ |
| Glen Santangelo★★★★★★★★★★#2956 · hits 52% · avg +4.5% | Barclays | $100 | Buy | +38.3% | Reiterated | 25.08.26on TipRanks Aug 26 04:15 | +1.7%next day −1.5% · 5 days −4.4% | ↗ |
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $95.00 → $85.00−10.5% | Buy | +17.6% | Reiterated | 24.08.26on TipRanks 11:05 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $95.00 → $82.00−13.7% | Hold | +13.4% | Downgrade | 24.08.26on TipRanks 11:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $92.00 → $82.00−10.9% | Hold | +13.4% | Downgrade | 24.08.26on TipRanks 11:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $88.00 → $80.00−9.1% | Hold | +10.7% | Reiterated | 24.08.26on TipRanks 11:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $95.00 → $84.00−11.6% | Buy | +16.2% | Reiterated | 24.08.26on TipRanks 11:05 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $87.00 | Buy | +20.3% | Reiterated | 24.08.26on TipRanks 11:05 | — | |
| Unknown Analyst | Jefferies | $120 | Buy | +66.0% | Reiterated | 10.08.26on TipRanks Aug 11 06:15 | −3.2%next day −1.3% · 5 days +0.4% | ↗ |
| Ekaterina Knyazkova★★★★★★★★★★#10740 · hits 30% · avg −10.6% | J.P. Morgan | $115 | Buy | +59.1% | Assigned | 10.08.26on TipRanks 07:30 | −3.2%next day −1.3% · 5 days +0.4% | ↗ |
| Gary Nachman★★★★★★★★★★#7384 · hits 47% · avg +0.3% | Canaccord Genuity | $91.00 → $90.00−1.1% | Hold | +24.5% | Reiterated | 10.08.26on TipRanks 07:07 | −3.2%next day −1.3% · 5 days +0.4% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $111 | Buy | +53.5% | Reiterated | 23.04.26on TipRanks 07:35 | −2.2%next day 0.0% · 5 days +0.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering ANI Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $107 at a price of $72.65 (+46.9%); now: $107 at $72.29 (+47.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 2 | 2 | 5 | 6 | 6 |
| Buy | 5 | 4 | 5 | 4 | 5 | 3 |
| Hold | 2 | 1 | 2 | 2 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $2.18 (from $2.02 to $2.33). Last quarter: $2.21.
Sales
Next quarter’s sales estimate — $280M (from $273M to $286M). Last quarter: $266M.
Best top-analyst consensus in the sector · Healthcare
About ANI Pharmaceuticals
- CEO: Nikhil Lalwani
- Employees: 970
- 210 Main Street West, Baudette, MN, 56623, US
- www.anipharmaceuticals.com
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Data from the stock’s TipRanks forecast page, read 16 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗